Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Yalcin
Bulent
B
Buyukcelik
Abdullah
A
Yalcin
Samet
S
Utkan
Gungor
G
Doruk
Hatice
H
Dogan
Mutlu
M
Altan
Mehmet
M
D001943:Breast Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D015986:Confounding Factors, Epidemiologic; D051546:Cyclooxygenase 2; D004311:Double-Blind Method; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D008565:Membrane Proteins; D015663:Osteoporosis, Postmenopausal / Q000150:complications*; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects*; D013923:Thromboembolism / Q000139:chemically induced*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases